TKT Predicts Replagal Will Win Race To Fabry Market, Orphan Exclusivity
Executive Summary
Transkaryotic Therapies anticipates Replagal will be the first Fabry's disease product to the U.S. market, TKT CEO Richard Selden, MD/PhD, told an earnings call Feb. 11